Legendary Trader: “Buy These Three Stocks Before this September Event”

Luke Lango believes an event scheduled for mid-September is set to trigger a massive market shock, potentially defining the winners and losers for the rest of the year.  

Wed, September 11 at 8:00PM ET
 
 
 
 
Register Here
Healthcare Stocks Icon

Healthcare Stocks

Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.

The words "recession proof" written on a pink sticky note. bulletproof stocks

7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024

These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.

Interest rate and dividend concept. Businessman with percentage symbol and up arrow, Interest rates continue to increase, return on stocks and mutual funds, long term investment for retirement. Dividend stocks

7 Dependable Dividend Stocks for Long-Term Income

Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.

medicine research, pharmaceutical background, LJPC stock

3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct

These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.

Other industries you might be interested in

Icon depicting a DNA strand

Biotech

Marijuana leaf

Cannabis

Icon depicting pills

Psychedelics

Recent Healthcare Stocks Articles

Why Is Achieve Life Sciences (ACHV) Stock Down 44% Today?

By William White, InvestorPlace Writer
Achieve Life Sciences stock is falling on Tuesday after the company provided ACHV investors with an FDA update concerning an NDA.

Why Is Bruush Oral Care (BRSH) Stock Up 18% Today?

By William White, InvestorPlace Writer
Bruush Oral Care stock is up on Tuesday as investors react to news of BRSH stock potentially regaining listing compliance.

Why Is Icosavax (ICVX) Stock Up 46% Today?

By William White, InvestorPlace Writer
Icosavax stock is up on Tuesday as investors react to an acquisition deal with AstraZeneca that values ICVX between $15 and $20 per share.

7 Stock Winners That Are Up 1,000% or More in 2023

By Thomas Niel, InvestorPlace Contributor
Could any or all of these seven stocks up 1000% this year go on another hot run during 2024? Let's find out.

3 Small-Cap Stocks to Scoop Up Before the New Year

By Rich Duprey, InvestorPlace Contributor
Smaller companies typically beat their bigger counterparts over time and these three high-potential small-cap stocks are ready to run now.

3 New Stock Listings That Can Deliver Multibagger Returns

By Faisal Humayun, InvestorPlace Contributor
New stock listings are poised for multibagger returns as they represent quality growth businesses in the coming years.

3 Cathie Wood Stocks to Sell Before It’s Too Late

By Terel Miles, InvestorPlace Contributor
Not all Cathie Wood Stocks are created equally. Therefore, investors should carefully consider dropping these Cathie Wood Stocks to sell.

The 7 Best Bargain Growth Stocks to Buy Before 2024

By Omor Ibne Ehsan
These bargain growth stocks offer significant upside potential alongside decent margins of safety, for those seeking impressive value.

3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023

By Ian Cooper, InvestorPlace Contributor
Some of the most explosive opportunities can be found in biotech stocks. In fact, as we head into New Year 2024, here are three to consider.

Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?

By William White, InvestorPlace Writer
Pasithea Therapeutics stock is climbing higher with heavy trading of KTTA shares alongside results from two preclinical trials.

CI Stock Alert: Cigna Ditches Humana Acquisition for $10 Billion Stock Buyback

By Larry Ramer, InvestorPlace Contributor
Cigna has reportedly canceled its plans to buy a rival health insurer, Humana. Instead, Cigna will buy $10 billion of CI stock. 

Russell 2000 Leaders: 7 Stocks Outperforming the Index

By Chris Markoch, InvestorPlace Contributor
If you have room in your portfolio for some risk-on assets, you can consider adding one or more of these Russell 2000 stocks.

Artificial Intelligence in Healthcare: 3 Stocks Transforming the Industry

By Alex Sirois, InvestorPlace Contributor
Companies are applying AI in healthcare which is leading to better outcomes and stronger performance for their stocks.

The 3 Best Cathie Wood Stocks to Buy in December

By Larry Ramer, InvestorPlace Contributor
Cathie Wood stocks had a great November and are well-positioned to keep performing well, given the favorable macro backdrop. 

The 3 Best Cheap Stocks to Buy in December

By Joel Baglole, InvestorPlace Contributor
Investors wanting to buy low and sell high should consider a position in one of these great companies whose shares have pulled back lately.

Future in Fitness: 3 Stocks Innovating in Digital Health

By Tyrik Torres, InvestorPlace Contributor
Benefitting from the tech transformations spurred by the pandemic, these three digital health stocks bring healthcare to the home.

Market Movers: Why Big Players Are Investing Millions in These 3 Stocks

By Yiannis Zourmpanos, InvestorPlace Contributor
In investing, certain stocks catch the discerning eye of big players, drawing in substantial investments.

Why Is Intensity Therapeutics (INTS) Stock Up 133% Today?

By William White, InvestorPlace Writer
Intensity Therapeutics stock is taking off on Thursday as investors in INTS react to positive results from a Phase 2 clinical trial.

Why Is Avid Bioservices (CDMO) Stock Down 18% Today?

By William White, InvestorPlace Writer
Avid Bioservices stock is falling hard on Friday as investors in CDMO react to a lackluster earnings report and a guidance cut.
Load More Articles